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Abstract
Taurine demonstrates multiple cellular functions including a central role as a neurotransmitter, as a trophic factor in CNS
development, in maintaining the structural integrity of the membrane, in regulating calcium transport and homeostasis,
as an osmolyte, as a neuromodulator and as a neuroprotectant. The neurotransmitter properties of taurine are
illustrated by its ability to elicit neuronal hyperpolarization, the presence of specific taurine synthesizing enzyme and
receptors in the CNS and the presence of a taurine transporter system. Taurine exerts its neuroprotective functions
against the glutamate induced excitotoxicity by reducing the glutamate-induced increase of intracellular calcium level,
by shifting the ratio of Bcl-2 and Bad ratio in favor of cell survival and by reducing the ER stress. The presence of
metabotropic taurine receptors which are negatively coupled to phospholipase C (PLC) signaling pathway through
inhibitory G proteins is proposed, and the evidence supporting this notion is also presented.
Introduction
Taurine, 2-amino-ethanesulfonic acid, is one of the
most abundant amino acids in mammals [1]. The phy-
siological role of taurine has received considerable
attention since the reports that cats fed a taurine defi-
cient diet developed central retinal degeneration [2]
and cardiomyopathy [3]. Now, taurine has been shown
to be involved in many important physiological func-
tions [for review, see [4]] e.g., as a trophic factor in the
development of the CNS [5] and, for instance, kittens
from the taurine-depleted mothers exhibit a delay in
the migration of cells in the cerebellum and in the
visual cortex [5]. It also serves in maintaining the
structural integrity of the membrane [6], regulating
calcium binding and transport [7,8], as an osmolyte
[9,10], a neuromodulator [11], a neurotransmitter
[12-18] and a neuroprotector against L-glutamate (L-
Glu)-induced neurotoxicity [19,20]. In this article, the
role of taurine in the central nervous system (CNS) as
a neurotransmitter, a neuro-protective agent and a
potent regulator for intracellular calcium homeostasis
will be reviewed.
Taurine as a neurotransmitter
In general, a substance can be accepted as a neurotrans-
mitter if it has fulfilled the following set of criteria:
firstly, the substance and/or its synthesizing enzyme has
to be present in the suspected neuron, preferably it is
concentrated at the nerve terminal; secondly, it is
released upon stimulation in a calcium-dependent man-
ner; thirdly, it elicits proper physiological response;
fourthly, a specific receptor is present and fifthly, an
inactivation mechanism is present to terminate the
action of the suspected neurotransmitter. The following
lines of evidence have supported the notion that taurine
is a neurotransmitter in the mammalian CNS: 1. The
presence of a specific enzyme responsible for taurine
biosynthesis in the brain, namely, cysteic/cysteine sulfi-
nic acid decarboxylase (CAD/CSAD) which is distinctly
different from the GABA-synthesizing enzyme, L-gluta-
mate decarboxylase (GAD) was reported [21,22]. Immu-
nocytochemical studies have revealed the localization of
CAD/CSAD in the cell body, dendrite as well as in the
nerve terminal [13][17][18][23][24-26]; 2. Release of
taurine has been shown to be either calcium dependent
or calcium independent [13]; 3. Taurine has been shown
to elicit neuronal hyperpolarization presumably through
its action by opening the chloride channels in the cere-
bellum [27] and in the hippocampus [14]; 4. The
presence of a specific taurine receptor has been
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specific taurine receptors which have Kd in nM range
and are distinctly different from GABAA,G A B A B and
glycine receptors since the agonists or antagonists of
these receptors have little effect on the binding of taur-
ine to taurine receptors [28]. Similar observations were
recently reported by Frosini et al [29]; 5. The presence
of a taurine transporter system for inactivation of its
function has also been reported [30]. In fact, taurine
transporters have been cloned [31] and taurine transpor-
ter knock-out transgenic mice have been established
[32]. In summary, taurine has fulfilled most if not all of
the criteria to be accepted as a neurotransmitter in the
mammalian CNS.
Regulation of intracellular calcium homeostasis
It is known that the level of intracellular free calcium,
[Ca
2+]i, is maintained at sub-micromolar concentration
by calcium sequestering into internal calcium storage
pools e.g., mitochondria, endoplasmic reticulum (ER) as
well as pumping out to the extracellular space by cal-
cium-ATPase. When neurons are stimulated by gluta-
mate, the [Ca
2+]I level is elevated due to influx of
calcium from extracellular sources through various cal-
cium channels including NMDA receptors, voltage-
gated calcium channels (VGCC) such as L-, N- and P/
Q-type, reverse mode of Na
+/Ca
2+ exchanger as well as
release of calcium from the internal calcium storage
pools. However, in the presence of taurine, glutamate-
induced increase of [Ca
2+]i is markedly reduced as
shown in Fig 1.
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one of the pathways by which taurine reduced glutamate-
induced elevation of [Ca
2+]i is through inhibition of Ca
2+
influx via the reverse mode of Na
+/Ca
2+ exchanger. At the
resting membrane potential, Na
+/Ca
2+ exchanger func-
tions to move Ca
2+ out of the cell. However, under depo-
larizing conditions such as under glutamate stimulation, it
reverses its function to facilitate Ca
2+ influx [34]. The
effect of taurine on Na
+/Ca
2+ exchanger has been sug-
gested to be in part due to in part its membrane stabilizing
activity [35]. It has been shown that phospholipid N-
methylation is associated with a decrease in Na
+/Ca
2+
exchanger activity [36]. Hence, taurine-mediated reduc-
tions in phospholipid N-methyltransferase activity enhance
efflux of Ca
2+ through the Na
+/Ca
2+ exchanger and lower
tissue Ca
2+ content. Taurine also promotes Ca
2+ efflux via
the Na
+/Ca
2+ exchanger by increasing [Ca
2+]i in the vici-
nity of the exchanger. [35]. In addition to Na
+/Ca
2+
exchanger, taurine also inhibits the release of Ca
2+ from
internal pools [37] as well as inhibits various voltage-gated
calcium channels (VGCC) such as L-, N- and P/Q-type
[38]. Although osmotic stress and taurine treatment were
reported to affect various channels such as the Na
+/Ca
2+
exchanger, the ATP-sensitive K
+ channel, the L-type
VGCC and the fast Na
+ channel [39], we believe that in
neuronal systems, the effect of taurine on various calcium
channels is likely due to a combination of counteraction of
glutamate-induced depolarization by taurine as well as
receptor-mediated G-protein coupled events. This notion
is supported by the following observations: First of all,
recently we have shown that when glutamate-induced
membrane depolarization is abolished by taurine as mea-
sured by voltage-sensitive dye, the VGCC activity is also
suppressed [38]. Secondly, Kaczmarek [40] reported that
exposure of isolated bag cell neurons to activators of
Figure 1 Effect of taurine on glutamate induced [Ca
2+]i
accumulation (A) confocal study - A. Baseline; B & J. Glutamate; C,
F & I. After washing; D. Nifedipine; E. Nifedipine plus glutamate; G.
Taurine; H. Taurine plus glutamate. Color coding indicates [Ca
2+]i,
red being the highest and blue the lowest. (B). Accumulation of
45Ca
2+ influx - 1. Control; 2. Glutamate; 3. Glutamate plus 25mM
taurine; 4. Glutamate plus 5mM taurine.
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Page 2 of 6Figure 2 A. Effect of taurine on PLC activity; B. A proposed model for the mode of action of taurine on the IP3 pathway. A. Effect of
taurine on PLC activity. 1). Control, 2). 0.25mM Glu, 3). 25mM taurine, 4). 25mM taurine plus 0.25mM Glu, 5). 10μM carbachol. The error bar
indicates the standard deviation with N=3. Briefly,
3H-inositol was used as precursor for [
3H]-phosphoinositides (PI). Hydrolysis of [PI] to inositol
phosphates, [IP]n, is an index of PLC activity. The experiments were performed as described previously [45]. Primary neuronal cultures in 35 mm
dishes were first labeled with 8μCi of [
3H, U]-inositol for 24 hours. The cells were washed with fresh medium containing 2mM LiCl (to prevent
IP3 dephosphorylation) and exposed to either Glu, taurine, or carbachol (a muscarinic cholinergic receptor agonist known to stimulate PLC), as
indicated. Phosphoinositides, [PI], and inositol phosphates, [IP]n, were determined from the organic phase and aqueous phase, respectively as
described [45]. The results are expressed as the ratio of [IP]n to [PI]. The results show that taurine reduces the production of basal level of [IP]n
by 20% (column 3) and Glu-stimulated increase of [IP]n production by 40% (column 4). This coupled with the above results suggest that taurine
may reduce the basal level or Glu-induced increase of poly-PI turnover through its inhibitory effect on PLC via inhibitory G-proteins e.g. Gi/Go-
like proteins. B. A proposed model for the mode of action of taurine on the IP3 pathway. Diagram illustrating that taurine’s action on
taurine receptors results in an inhibition of PLC activity causing a reduction in IP3 formation thus reducing IP3 mediated release of calcium from
internal stores.
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voltage-dependent calcium current. Since taurine can pre-
vent protein phosphorylation, such as of its own synthesiz-
ing enzyme, CSAD [41], it is reasonable to believe that
taurine also can prevent glutamate-induced VGCC activa-
tion by inhibiting phosphorylation of these channel pro-
teins. Thirdly, previously we reported the presence of
specific taurine receptors which have Kd in nM range and
are distinctly different from GABAA, GABAB, glycine and
glutamate receptors since the agonists or antagonists of
these receptors have little effect on the binding of taurine
to taurine receptors [42]. Similar observations were also
reported by Frosini et al [29]. Furthermore, the binding of
taurine to taurine receptors is inhibited by GTP or its
non-hydrolyzable GTP analog, [g-S]-GTP, in a dose-
dependent manner [43]. It is believed that binding of GTP
to the a-subunit of G-protein promotes the dissociation of
G-protein from the receptors resulting in the conversion
of receptors back to their low affinity conformation.
Fourthly, the inhibitory effect of GTP on taurine receptor
binding disappeared once G-proteins were removed from
the receptors by treating the membranes with a low con-
centration of Triton X-100 [43]. Fifthly, Glu-induced ele-
vation of [Ca
2+]i in the absence of extracellular Ca
2+ is
inhibited by taurine suggesting that taurine inhibits the
Glu-induced release of Ca
2+ from the internal pools [37].
It is of interest that GABAB receptor agonists such as
baclofen were reported to inhibit a variety of VGCCs
including L-, N- and P/Q-type VGCC through GABAB
receptor-coupled inhibitory G-proteins, Go and Gi [44].
Here we propose that similar to the GABAB receptors,
when the metabotropic taurine receptors (mTauR) are
activated by taurine, the coupled inhibitory G-proteins e.g.
Go/Gi are then activated resulting in inhibition of VGCCs.
Furthermore, we propose that mTauR are negatively
coupled to phospholipase C (PLC) through inhibitory G-
p r o t e i n s ,e . g .G o/Gi analogous to the GABAB receptors
which are negatively coupled to adenylyl cyclase through
inhibitory G-proteins [44]. Activation of taurine receptors
by taurine would lead to inhibition of PLC activity (Fig 2),
resulting in reduction in IP3 formation and hence
IP3-mediated release of Ca
2+ from the internal pools.
Taurine as a neuroprotective agent
One important function of taurine is its neuro-protective
function. We [19,33] as well as others [20] have shown
that taurine can effectively prevent glutamate-induced
neuronal injury in cultured neurons. In addition, we have
 
Figure 3 A model depicting the pathway that taurine exerts its function against glutamate-induced apoptosis. Taurine’s neuroprotective
functions are due to its role in reducing intracellular free calcium concentration and its antioxidative stress capacity. Taurine can shift the ratioo f
anti-apoptotic Bcl-2 protein and pro-apoptotic Bax protein towards cell survival. As shown in the diagram taurine inhibits glutamate-induced
activation of calcium and the subsequent heterodimerization of Bcl-2 and Bax protein resulting in the apoptosis cascade.
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Page 4 of 6also demonstrated that taurine can protect against H2O2-
induced cell injury in PC12 cell cultures by reducing
H2O2-induced ER stress (Pan et al 2010, in this issue). It
is generally believed that taurine’s neuroprotective func-
tions are due to its role in reducing intracellular free
Ca
2+ concentration, [Ca
2+]i, and its anti-oxidative stress
capacity [33,35]. We have recently shown that taurine
can shift the ratio of the anti-apoptotic protein, Bcl-2 and
the pro-apoptotic protein, Bax, in favor of cell survival
[38]. In addition, we have also demonstrated that gluta-
mate-induced activation of calpain is inhibited by taurine
resulting in decrease of formation of hetero-dimers of
Bcl-2 and Bax and the subsequent release of cytochrome
C and the apoptosis cascade [38]. The sequence of events
by which that taurine exerts its neuroprotective function
can be summarized as follows:
1. Taurine reduces glutamate-induced elevation of
[Ca
2+]I by inhibiting calcium influx from various cal-
cium channels including the reverse mode of Na
+/Ca
2+
exchanger, various voltage-gated calcium channels
(VGCC) such as L-, N- and P/Q-type, and glutamate
NMDA receptors.
2. Taurine inhibits phosphorylation of VGCC resulting
in decrease of calcium influx 3. Taurine also reduces the
release of calcium from the internal storage pools
presumably due to inhibition of phospholipase C.
3. Taurine inhibits glutamate-induced activation of
calpain and the subsequent hetero-dimerization of Bcl-2
and Bax protein resulting in inhibition of release of
cytochrome C and the apoptosis cascade (Fig 3).
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